CL2008003181A1 - Sal del acido 3-[5-(piridin-2-il-metoxi)-3-(2-metil-2-propiltio)-1-[4-(2-metoxipiridin-5-il)bencil]-indol-2-il]-2,2-dimetil-propionico; fromas crsitalinas de la sal sodica; proceso de preparacion; composiciones farmaceuticas; kit farmaceutico, y uso para el tratamiento de asma. - Google Patents

Sal del acido 3-[5-(piridin-2-il-metoxi)-3-(2-metil-2-propiltio)-1-[4-(2-metoxipiridin-5-il)bencil]-indol-2-il]-2,2-dimetil-propionico; fromas crsitalinas de la sal sodica; proceso de preparacion; composiciones farmaceuticas; kit farmaceutico, y uso para el tratamiento de asma.

Info

Publication number
CL2008003181A1
CL2008003181A1 CL2008003181A CL2008003181A CL2008003181A1 CL 2008003181 A1 CL2008003181 A1 CL 2008003181A1 CL 2008003181 A CL2008003181 A CL 2008003181A CL 2008003181 A CL2008003181 A CL 2008003181A CL 2008003181 A1 CL2008003181 A1 CL 2008003181A1
Authority
CL
Chile
Prior art keywords
methoxypyridin
propylthio
indol
pyridin
asthma
Prior art date
Application number
CL2008003181A
Other languages
English (en)
Inventor
Petpiboon Peppi Prasit
Jillian F Evans
Melissa Virginia Rewolinski
Kevin Murray Schaab
Christopher David King
Original Assignee
Amira Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amira Pharmaceuticals Inc filed Critical Amira Pharmaceuticals Inc
Publication of CL2008003181A1 publication Critical patent/CL2008003181A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Otolaryngology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Composición farmacéutica que comprende el ácido 3-[5-(piridin-2-il-metoxi)-3-(2-metil-2-propiltio)-1-[4-(2-metoxipiridin-5-il)bencil]-indol-2-il]-2,2-dimetil-propiónico; sal del compuesto; su forma cristalina; proceso para prepararla; y uso para el tratamiento del asma.
CL2008003181A 2007-10-26 2008-10-24 Sal del acido 3-[5-(piridin-2-il-metoxi)-3-(2-metil-2-propiltio)-1-[4-(2-metoxipiridin-5-il)bencil]-indol-2-il]-2,2-dimetil-propionico; fromas crsitalinas de la sal sodica; proceso de preparacion; composiciones farmaceuticas; kit farmaceutico, y uso para el tratamiento de asma. CL2008003181A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98312407P 2007-10-26 2007-10-26
US98311907P 2007-10-26 2007-10-26

Publications (1)

Publication Number Publication Date
CL2008003181A1 true CL2008003181A1 (es) 2009-03-06

Family

ID=40580422

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2008003181A CL2008003181A1 (es) 2007-10-26 2008-10-24 Sal del acido 3-[5-(piridin-2-il-metoxi)-3-(2-metil-2-propiltio)-1-[4-(2-metoxipiridin-5-il)bencil]-indol-2-il]-2,2-dimetil-propionico; fromas crsitalinas de la sal sodica; proceso de preparacion; composiciones farmaceuticas; kit farmaceutico, y uso para el tratamiento de asma.

Country Status (17)

Country Link
US (1) US8697730B2 (es)
EP (1) EP2212312A4 (es)
JP (1) JP2011500846A (es)
KR (1) KR20100080561A (es)
CN (1) CN101910154A (es)
AR (1) AR068947A1 (es)
AU (1) AU2008316615A1 (es)
BR (1) BRPI0818831A2 (es)
CA (1) CA2702798A1 (es)
CL (1) CL2008003181A1 (es)
EA (1) EA201000486A1 (es)
MX (1) MX2010004501A (es)
PE (1) PE20090948A1 (es)
TW (1) TW200920369A (es)
UY (1) UY31431A1 (es)
WO (1) WO2009055721A2 (es)
ZA (1) ZA201002692B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8399666B2 (en) 2005-11-04 2013-03-19 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
GB2431927B (en) 2005-11-04 2010-03-17 Amira Pharmaceuticals Inc 5-Lipoxygenase-activating protein (FLAP) inhibitors
US7977359B2 (en) 2005-11-04 2011-07-12 Amira Pharmaceuticals, Inc. 5-lipdxygenase-activating protein (FLAP) inhibitors
WO2008067566A1 (en) * 2006-11-30 2008-06-05 Amira Pharmaceuticals, Inc. Compositions and treatments comprising 5-lipoxygenase-activating protein inhibitors and nitric oxide modulators
JP5791500B2 (ja) 2008-05-23 2015-10-07 パンミラ ファーマシューティカルズ，エルエルシー． ５−リポキシゲナーゼ活性化タンパク質阻害剤
EP2550269B1 (en) * 2010-03-23 2016-03-23 Scinopharm Taiwan Ltd. Process and intermediates for preparing lapatinib
KR101137929B1 (ko) * 2010-05-31 2012-05-09 에스케이하이닉스 주식회사 비휘발성 메모리 장치 및 그 제조 방법
WO2014031586A2 (en) * 2012-08-20 2014-02-27 Tallikut Pharmaceuticals, Inc. Methods for treating cardiovascular diseases
US8807131B1 (en) 2013-06-18 2014-08-19 Isonea Limited Compliance monitoring for asthma inhalers
KR101822767B1 (ko) 2013-12-13 2018-01-26 에프. 호프만-라 로슈 아게 브루톤 티로신 키나아제의 억제제
US9624201B2 (en) 2013-12-13 2017-04-18 Hoffmann-La Roche Inc. Inhibitors of bruton's tyrosine kinase
JP6219523B2 (ja) 2013-12-13 2017-10-25 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ブルトンチロシンキナーゼの阻害剤
ES2878405T3 (es) 2014-02-04 2021-11-18 Bioscience Pharma Partners Llc Uso de inhibidores de flap para reducir la lesión mediada por neuroinflamación en el sistema nervioso central
ES2946184T3 (es) * 2015-12-08 2023-07-13 Biomatrica Inc Reducción de la velocidad de eritrosedimentación
CN112126986B (zh) * 2020-04-30 2023-07-18 苏州京脉生物科技有限公司 一种定量miRNA的测序文库制备和分析方法
CN115267002A (zh) * 2022-08-08 2022-11-01 江苏慧聚药业股份有限公司 Gc-ms/ms联用测定醰露替尼中游离肼的方法
CN117665187B (zh) * 2023-11-23 2024-08-16 宁波大红鹰药业股份有限公司 一种舒林酸中间体杂质的测定方法

Family Cites Families (126)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2431491A1 (fr) 1978-07-18 1980-02-15 Delalande Sa Nouveaux derives aminoalkoxy-5 benzofurannes et indoles, leur procede de preparation et leur application en therapeutique
DK151884C (da) 1979-03-07 1988-06-13 Pfizer Analogifremgangsmaade til fremstilling af 3-(1-imidazolylalkyl)indolderivater eller farmaceutisk acceptable syreadditionssalte deraf
JPS60123485A (ja) 1983-12-08 1985-07-02 Yoshitomi Pharmaceut Ind Ltd インド−ル−３−カルボキサミド誘導体
US5109009A (en) 1985-03-08 1992-04-28 Leo Pharmaceutical Products Ltd. Quinoline and pyridine compounds and inhibition of 5-lipoxygenases therewith
IE58870B1 (en) 1985-03-08 1993-11-17 Leo Pharm Prod Ltd Pyridine derivatives
US5081138A (en) 1986-12-17 1992-01-14 Merck Frosst Canada, Inc. 3-hetero-substituted-n-benzyl-indoles and prevention of leucotriene synthesis therewith
US5225421A (en) 1986-12-17 1993-07-06 Merck Frosst Canada, Inc. 3-hetero-substituted-N-benzyl-indoles and medical methods of use therefor
US5232916A (en) 1988-06-27 1993-08-03 Merck Frosst Canada, Inc. Quinoline ether alkanoic acids
US5252585A (en) 1992-02-03 1993-10-12 Merck Frosst Canada, Inc. Fluorinated quinoline indoles as inhibitors of the biosynthesis of leukotrienes
NZ234883A (en) 1989-08-22 1995-01-27 Merck Frosst Canada Inc Quinolin-2-ylmethoxy indole derivatives, preparation and pharmaceutical compositions thereof
US5272145A (en) 1989-08-22 1993-12-21 Merck Frosst Canada, Inc. (Quinolin-2-ylmethoxy)indoles as inhibitors of the biosynthesis of leukotrienes
CA1337427C (en) 1989-08-22 1995-10-24 Merck Frosst Canada Incorporated (quinolin-2-ylmethoxy)indoles as inhibitors of the biosynthesis of leukotrienes
US5204344A (en) 1989-08-22 1993-04-20 Merck Frosst Canada, Inc. (Quinolin-2-ylmethoxy)indoles as inhibitors of the biosynthesis of leukotrienes
US5229516A (en) 1989-10-27 1993-07-20 American Home Products Corporation Substituted indole-, indene-, pyranoindole- and tetrahydrocarbazole-alkanoic acid derivatives as inhibitors of PLA2 and lipoxygenase
US5420289A (en) 1989-10-27 1995-05-30 American Home Products Corporation Substituted indole-, indene-, pyranoindole- and tetrahydrocarbazole-alkanoic acid derivatives as inhibitors of PLA2 and lipoxygenase
CA2032253C (en) 1989-12-15 2000-11-28 John W. Gillard 5-lipoxygenase activating protein
US5093356A (en) * 1990-01-16 1992-03-03 Merck Frosst Canada, Inc. Indenyl hydroxamic acids and hydroxy ureas as inhibitors of 5-lipoxygenase
US5081145A (en) 1990-02-01 1992-01-14 Merck Frosst Canada, Inc. Indole-2-alkanoic acids compositions of and anti allergic use thereof
US5095031A (en) 1990-08-20 1992-03-10 Abbott Laboratories Indole derivatives which inhibit leukotriene biosynthesis
JPH0764841B2 (ja) 1990-10-03 1995-07-12 ファイザー製薬株式会社 インドール誘導体およびその用途
US5182367A (en) 1990-11-30 1993-01-26 Merck & Co., Inc. 5-lipoxygenase activating protein
GB9108811D0 (en) 1991-04-24 1991-06-12 Erba Carlo Spa N-imidazolyl derivatives of substituted indole
US5202321A (en) 1991-06-13 1993-04-13 Merck Frosst Canada, Inc. Thiopyrano[2,3,4-c,d]indoles as inhibitors of leukotriene biosynthesis
JPH06100551A (ja) 1991-09-06 1994-04-12 Dainippon Ink & Chem Inc 光学活性な２，５置換テトラヒドロフラン誘導体、その製造方法、その誘導体を含む液晶組成物及び液晶表示素子
US5190968A (en) 1991-09-30 1993-03-02 Merck Frosst Canada, Inc. (Polycyclic-arylmethoxy) indoles as inhibitors of leukotriene biosynthesis
US5389650A (en) 1991-09-30 1995-02-14 Merck Frosst Canada, Inc. (Azaarylmethoxy)indoles as inhibitors of leukotriene biosynthesis
US5308850A (en) 1991-09-30 1994-05-03 Merck Frosst Canada, Inc. (Bicyclic-hetero-arylmethoxy)indoles as inhibitors of leukotriene biosynthesis
US5290798A (en) 1991-09-30 1994-03-01 Merck Frosst Canada, Inc. (hetero-arylmethoxy)indoles as inhibitors of leukotriene biosynthesis
CA2079374C (en) 1991-09-30 2003-08-05 Merck Frosst Canada Incorporated (bicyclic-azaarylmethoxy)indoles as inhibitors of leukotriene biosynthesis
US5273980A (en) 1991-09-30 1993-12-28 Merck Frosst Canada Inc. Bicyclic-azaarylmethoxy) indoles as inhibitors of leukotriene biosynthesis
ZA928276B (en) 1991-10-31 1993-05-06 Daiichi Seiyaku Co Aromatic amidine derivates and salts thereof.
US5254567A (en) 1991-11-15 1993-10-19 Merck Frosst Canada, Inc. Amorphous (quinolin-2-ylmethoxy)indole compounds which have useful pharmaceutical utility
CH683522A5 (de) 1992-03-13 1994-03-31 Hoffmann La Roche Verfahren zur Herstellung von Diarylen.
EP0597112A4 (en) 1992-03-27 1994-06-22 Kyoto Pharma Ind Novel imidazole derivative, pharmaceutical use thereof, and intermediate therefor.
FI944549L (fi) 1992-04-02 1994-11-30 Smithkline Beecham Corp Allergisten ja tulehdussairauksien hoidossa käyttökelpoiset yhdisteet
JPH0658881A (ja) 1992-06-12 1994-03-04 Mitsubishi Rayon Co Ltd 光学活性化合物の絶対配置判定法、絶対配置判定用試薬及び絶対配置判定装置
US5334719A (en) 1992-06-17 1994-08-02 Merck Frosst Canada, Inc. Bicyclic(azaaromatic)indoles as inhibitors of leukotriene bisynthesis
US5314898A (en) 1992-06-29 1994-05-24 Merck & Co., Inc. Aryl thiopyrano[4,3,2-cd]indoles as inhibitors of leukotriene biosynthesis
US5288743A (en) 1992-11-20 1994-02-22 Abbott Laboratories Indole carboxylate derivatives which inhibit leukotriene biosynthesis
JP3457694B2 (ja) 1993-02-04 2003-10-20 第一製薬株式会社 インフルエンザ感染予防・治療薬
US5374635A (en) 1993-03-29 1994-12-20 Merck Frosst Canada, Inc. Furo[3,2-b]pyridines and thieno[3,2-b]pyridines as inhibitors of leukotriene biosynthesis
JPH075651A (ja) 1993-06-14 1995-01-10 Fuji Photo Film Co Ltd ハロゲン化銀カラー写真感光材料の処理方法
DE4338770A1 (de) 1993-11-12 1995-05-18 Matthias Dr Lehr Indol-2-alkansäuren und ihre Derivate als Hemmstoffe der Phospholipase A¶2¶
US5399699A (en) 1994-01-24 1995-03-21 Abbott Laboratories Indole iminooxy derivatives which inhibit leukotriene biosynthesis
US5420282A (en) 1994-02-15 1995-05-30 Abbott Laboratories Thiopyrano(2,3,4-c,d) indolyloxime ether alkylcarboxylates
US5696076A (en) 1994-06-22 1997-12-09 Human Genome Sciences, Inc. 5-lipoxygenase-activating protein II
FR2721610B1 (fr) 1994-06-28 1996-08-23 Adir Nouveaux dérivés (thia)cycloalkyl [b] indoles, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
JPH0820532A (ja) 1994-07-05 1996-01-23 Dai Ichi Seiyaku Co Ltd 抗膵炎剤
TW396200B (en) 1994-10-19 2000-07-01 Sumitomo Chemical Co Liquid crystal composition and liquid crystal element containing such composition
US5702637A (en) 1995-04-19 1997-12-30 Minnesota Mining And Manufacturing Company Liquid crystal compounds having a chiral fluorinated terminal portion
JPH092977A (ja) 1995-06-21 1997-01-07 Dai Ichi Seiyaku Co Ltd 経口投与用医薬組成物
US5750558A (en) 1996-06-06 1998-05-12 Abbott Laboratories Oxime derivatives of indole and indene compounds as inhibitors of prostaglandin biosynthesis
US5877329A (en) 1996-08-13 1999-03-02 Merck & Co., Inc. Palladium catalyzed indolization
JPH1180032A (ja) 1997-09-12 1999-03-23 Dai Ichi Seiyaku Co Ltd 複合体
JPH11193265A (ja) 1997-12-26 1999-07-21 Dai Ichi Seiyaku Co Ltd ３−（７−アミジノ−２−ナフチル）−２−フェニルプロピオン酸誘導体の塩
JPH11189531A (ja) 1997-12-26 1999-07-13 Dai Ichi Seiyaku Co Ltd 経粘膜投与用医薬組成物
CA2260499A1 (en) 1998-01-29 1999-07-29 Sumitomo Pharmaceuticals Company Limited Pharmaceutical compositions for the treatment of ischemic brain damage
US6500853B1 (en) 1998-02-28 2002-12-31 Genetics Institute, Llc Inhibitors of phospholipase enzymes
DE69933661T3 (de) 1998-04-15 2012-01-26 Merck Serono Biodevelopment Genomische sequenz des 5-lipoxygenase-aktivierenden proteins (flap), polymorphische marker und ihre anwendung in der diagnose von asthma
US6867209B1 (en) 1998-05-22 2005-03-15 Scios, Inc. Indole-type derivatives as inhibitors of p38 kinase
JP2000007590A (ja) 1998-06-23 2000-01-11 Daicel Chem Ind Ltd 置換芳香族化合物の製造方法
JP2000302671A (ja) 1999-04-27 2000-10-31 Hitoshi Sezaki 経口投与用医薬組成物
DE19948417A1 (de) 1999-10-07 2001-04-19 Morphochem Ag Imidazol-Derivate und ihre Verwendung als Arzneimittel
JP2001139462A (ja) 1999-11-10 2001-05-22 Dai Ichi Seiyaku Co Ltd 新規製剤
US20010039037A1 (en) 2000-04-05 2001-11-08 Lee Harland Novel polypeptide
MXPA02010763A (es) 2000-06-14 2003-03-10 Warner Lambert Co Heterociclicos biciclos-6,5 fusionados.
JP2002226429A (ja) 2001-02-06 2002-08-14 Fuji Photo Film Co Ltd アクリル酸エステル化合物の製造方法
US6627646B2 (en) 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs
EP1314733A1 (en) 2001-11-22 2003-05-28 Aventis Pharma Deutschland GmbH Indole-2-carboxamides as factor Xa inhibitors
USH2153H1 (en) 2002-04-24 2006-04-04 Smithkline Beecham Corp. Association of asthma with polymorphisms in the cysteinyl leukotriene 2 receptor
US20050209477A1 (en) 2002-06-20 2005-09-22 Sachiko Kato Process for producing vinyl perfluoroalkanesulfonate derivative
CA2495943C (en) 2002-08-29 2009-07-21 Merck & Co., Inc. Indoles having anti-diabetic activity
WO2004048331A1 (en) 2002-11-28 2004-06-10 Suven Life Sciences Limited N-arylalkyl-3-aminoalkoxyindoles and their use as 5-ht ligands
US20040198800A1 (en) 2002-12-19 2004-10-07 Geoffrey Allan Lipoxygenase inhibitors as hypolipidemic and anti-hypertensive agents
GB0301350D0 (en) 2003-01-21 2003-02-19 Merck Sharp & Dohme Therapeutic agents
JP4513351B2 (ja) 2003-02-12 2010-07-28 チッソ株式会社 結合基にフッ素化されたアルキル基を有する液晶性化合物、液晶組成物および液晶表示素子
WO2004078719A1 (ja) 2003-03-06 2004-09-16 Ono Pharmaceutical Co., Ltd. インドール誘導体化合物およびその化合物を有効成分とする薬剤
EP1479677A1 (en) 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH New indole derivatives as factor xa inhibitors
WO2004108671A1 (en) 2003-06-06 2004-12-16 Suven Life Sciences Limited Substituted indoles with serotonin receptor affinity, process for their preparation and pharmaceutical compositions containing them
US7629467B2 (en) 2003-07-24 2009-12-08 Merck & Co., Inc. Diphenyl substituted cycloalkanes, compositions containing such compounds and methods of use
WO2005019381A1 (en) 2003-08-25 2005-03-03 Merck Patent Gmbh Liquid crystalline medium
WO2005023246A1 (en) 2003-09-04 2005-03-17 Aventis Pharmaceuticals Inc. Substituted indoles as inhibitors of poly (adp-ribose) polymerase (parp)
JP4363133B2 (ja) 2003-09-09 2009-11-11 東洋インキ製造株式会社 有機エレクトロルミネッセンス用素子材料およびそれを用いた有機エレクトロルミネッセンス素子
US7268159B2 (en) 2003-09-25 2007-09-11 Wyeth Substituted indoles
JP2005170939A (ja) 2003-11-20 2005-06-30 Takeda Chem Ind Ltd 糖尿病の予防・治療剤
WO2005054176A1 (en) 2003-11-25 2005-06-16 Eli Lilly And Company Peroxisome proliferator activated receptor modulators
WO2005054213A1 (ja) 2003-12-02 2005-06-16 Shionogi & Co., Ltd. ペルオキシソーム増殖活性化受容体アゴニスト活性を有するイソキサゾール誘導体
WO2005054193A1 (en) 2003-12-03 2005-06-16 Merck & Co. Inc. 1-alkyl-3-thio-substituted indole-2-alkynoic acids useful for the treatment for alzheimer's disease and related conditions
JP5142450B2 (ja) 2003-12-25 2013-02-13 徹也 西尾 ジアミノ化合物、ビニル化合物、高分子化合物、配向膜、該配向膜を用いた有機半導体装置、導電性高分子、該導電性高分子を使用したエレクトロルミネッセンス素子、液晶配向膜、及び該液晶配向膜を用いた光学素子
WO2005066157A1 (en) 2004-01-02 2005-07-21 Suven Life Sciences 3-(pyrolidin-3-l) indoles as 5-ht6 receptor modulators
JP2005194250A (ja) 2004-01-09 2005-07-21 Sumitomo Chemical Takeda Agro Co Ltd トリアゾール化合物、その製造法および用途
EP1727533A1 (en) 2004-02-26 2006-12-06 Merck & Co., Inc. Use of cysteinyl leukotriene 2 receptor antagonists
MXPA06012683A (es) 2004-05-03 2007-01-16 Hoffmann La Roche Derivados de indolilo como moduladores de receptor x del higado.
MXPA06014536A (es) 2004-06-18 2007-06-05 Biolipox Ab Indoles utiles en el tratamiento de inflamacion.
US7625933B2 (en) 2004-07-02 2009-12-01 Merck & Co., Inc. Indoles having anti-diabetic activity
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
WO2006041961A1 (en) 2004-10-05 2006-04-20 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTHAND HUMAN SERVICES Arylthioindole tubulin polymerization inhibitors and methods of treating or preventing cancer using same
ES2345997T3 (es) 2005-01-14 2010-10-07 Janssen Pharmaceutica Nv Pirazolopiramidinas como inhibidores de las quinasas del ciclo celular.
WO2006077364A1 (en) 2005-01-19 2006-07-27 Biolipox Ab Indoles useful in the treatment of inflammation
JP2008527028A (ja) 2005-01-19 2008-07-24 バイオリポックス エービー 炎症の治療に有用なインドール類
WO2006077366A1 (en) 2005-01-19 2006-07-27 Biolipox Ab Indoles useful in the treatment of inflammation
WO2006077367A1 (en) 2005-01-19 2006-07-27 Biolipox Ab Indoles useful in the treatment of inflamation
CA2600860A1 (en) 2005-03-09 2006-09-21 Merck & Co., Inc. Diphenyl substituted cycloalkanes, compositions containing such compounds and methods of use
ATE524182T1 (de) 2005-04-21 2011-09-15 Merck Serono Sa 2,3-substituierte pyrazinsulfonamide als crth2- hemmer
GB0516156D0 (en) 2005-08-05 2005-09-14 Eisai London Res Lab Ltd JNK inhibitors
US7405302B2 (en) * 2005-10-11 2008-07-29 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein (FLAP) inhibitors
US8138360B2 (en) 2005-10-11 2012-03-20 University of Pittsburgh—of the Commonwealth System of Higher Education Isotopically-labeled benzofuran compounds as imaging agents for amyloidogenic proteins
GB2431927B (en) 2005-11-04 2010-03-17 Amira Pharmaceuticals Inc 5-Lipoxygenase-activating protein (FLAP) inhibitors
US20070219206A1 (en) * 2005-11-04 2007-09-20 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein (flap) inhibitors
US20070225285A1 (en) 2005-11-04 2007-09-27 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein (flap) inhibitors
US20070244128A1 (en) 2005-11-04 2007-10-18 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein (flap) inhibitors
US7977359B2 (en) * 2005-11-04 2011-07-12 Amira Pharmaceuticals, Inc. 5-lipdxygenase-activating protein (FLAP) inhibitors
US8399666B2 (en) 2005-11-04 2013-03-19 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
UY29896A1 (es) 2005-11-04 2007-06-29 Astrazeneca Ab Nuevos derivados de cromano, composiciones farmacéuticas conteniéndolos, procesos de preparación y aplicaciones
UY29892A1 (es) 2005-11-04 2007-06-29 Astrazeneca Ab Nuevos derivados de cromano, composiciones farmaceuticas conteniendolos, procesos de preparacion y aplicaciones
TW200815377A (en) 2006-04-24 2008-04-01 Astellas Pharma Inc Oxadiazolidinedione compound
JP5564251B2 (ja) 2006-06-29 2014-07-30 キネックス ファーマシューティカルズ， エルエルシー キナーゼカスケードを調節するためのビアリール組成物および方法
JP2009023986A (ja) 2006-11-08 2009-02-05 Pharma Ip 抗癌剤としてのビアリール誘導体
PL2848610T3 (pl) 2006-11-15 2018-01-31 Ym Biosciences Australia Pty Inhibitory aktywności kinazy
WO2008067566A1 (en) 2006-11-30 2008-06-05 Amira Pharmaceuticals, Inc. Compositions and treatments comprising 5-lipoxygenase-activating protein inhibitors and nitric oxide modulators
WO2008097930A1 (en) 2007-02-05 2008-08-14 Amira Pharmaceuticals, Inc. Reverse indoles as 5-lipoxygenase-activating protein (flap) inhibitors
US8039505B2 (en) 2007-04-11 2011-10-18 University Of Utah Research Foundation Compounds for modulating T-cells
WO2009002746A1 (en) 2007-06-22 2008-12-31 Decode Genetics Ehf. Dosing schedules of leukotriene synthesis inhibitors for human therapy
JP5791500B2 (ja) 2008-05-23 2015-10-07 パンミラ ファーマシューティカルズ，エルエルシー． ５−リポキシゲナーゼ活性化タンパク質阻害剤
US8546431B2 (en) 2008-10-01 2013-10-01 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
WO2011054783A2 (en) 2009-11-03 2011-05-12 Glaxo Group Limited Novel processes

Also Published As

Publication number Publication date
US8697730B2 (en) 2014-04-15
AU2008316615A1 (en) 2009-04-30
PE20090948A1 (es) 2009-07-27
EP2212312A4 (en) 2011-10-05
MX2010004501A (es) 2010-05-13
CA2702798A1 (en) 2009-04-30
WO2009055721A2 (en) 2009-04-30
EP2212312A2 (en) 2010-08-04
US20100075934A1 (en) 2010-03-25
CN101910154A (zh) 2010-12-08
BRPI0818831A2 (pt) 2015-04-22
UY31431A1 (es) 2009-05-29
EA201000486A1 (ru) 2010-12-30
KR20100080561A (ko) 2010-07-08
ZA201002692B (en) 2011-06-29
WO2009055721A3 (en) 2009-08-20
TW200920369A (en) 2009-05-16
JP2011500846A (ja) 2011-01-06
AR068947A1 (es) 2009-12-16

Similar Documents

Publication Publication Date Title
EA201100030A1 (ru) Пиразольные соединения 436
WO2012017239A3 (en) 4-(1h-indol-3-yl) -pyrimidines as alk inhibitors
MX2013014348A (es) Compuestos fungicidas de 1-{2-[2-halo-4-(4-halogen-fenoxi)-feni]-2 -alcoxi-2-ciclil-etil}-1h-[1,2,4]triazol sustituidos.
UA110310C2 (uk) Сполуки n-арилтриазолу як антагоністи рецепторів лізофосфатидної кислоти (lpar)
MX2013002713A (es) Imidazopiridazinas sustituidas.
CL2012001391A1 (es) Compuestos derivados de triazolopiridina sustituidos, inhibidores de la quinasa mps-1; composición farmacéutica; procedimiento de preparacion; combinación farmacéutica y uso para la profilaxis o tratamiento de una enfermedad hiperproliferativa tal como tumores hematológicos, sólidos y/o sus metástasis; compuestos intermediarios.
EA201100969A1 (ru) Солевые формы органического соединения
GEP20135785B (en) Pyrrolopyrimidine compounds as cdk inhibitors
EA201391720A1 (ru) Замещенные диоксопиперидинилфталимидные производные
WO2010011772A3 (en) Tri-cyclic pyrazolopyridine kinase inhibitors
HN2011000699A (es) El compuesto (s)-1-({4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il}-amida) de 2-amida del acido pirrolidin-1,2-dicarboxilico en forma libre o de sal y composiciones y composicion farmaceutica que lo contiene.
EA200970967A1 (ru) Оксадиазол замещенные производные индазола для применения в качестве агонистов сфингозин 1-фосфата (sip)
EA200901138A1 (ru) Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
MX2014001671A (es) Compuestos fungicidas de 1-{2-[2-halo-4-(4-halogen-fenoxi)-fenil]- 2-aluiniloxi-etil}-1h[1,2,4]triazol sustituidos.
CL2004001366A1 (es) Compuestos derivados de 2-(6-amino-piridin-2-il)-2-hidroxietilamino sustituidos, agonistas b2-adrenoceptores; procedimiento de preparacion; composicion farmaceutica; composicion farmaceutica y uso del compuesto en el tratamiento de asma, bronquitis c
UA109868C2 (ru) Соединения n-алкилтриазола как антагонисты лизофосфатидной кислоты (lpar)
UY32156A (es) Derivados sustituidos de la n2 - [1-(5 - fluoropirimidin -2-il) etil] - n4 - (1-metil - 1h-imidazol - 4 - il)) - pirimidina - 2,4 - diaminas y sus sales farmacéuticamente aceptables, proceso de preparación, composiciones conteniéndolos y aplicaciones.
UA104489C2 (uk) Сполуки для лікування дисліпідемії та споріднених хвороб
PH12013500301A1 (en) Oxadiazole inhibitors of leukotriene production
EA201000702A1 (ru) Некоторые производные 2-пиразинона и их применение в качестве ингибиторов нейтрофильной эластазы
EA201291217A1 (ru) ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ ПРОИЗВОДНЫЕ 1-(β-D-ГЛЮКОПИРАНОЗИЛ)-2-ТИЕНИЛМЕТИЛБЕНЗОЛА КАК ИНГИБИТОРЫ НЗПГ
GEP20135744B (en) Quinuclidine carbonate derivatives and medicinal compositions containing the same
CL2007001482A1 (es) Compuestos derivados de pirrolidin-2-amida sustituidas, inhibidores de proteasa activadora de canal; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como disquinesia ciliar primaria, carcinoma pulmonar, bronquitis cronica, e
PE20090948A1 (es) Inhibidor de la proteina activadora de la 5-lipoxigenasa (flap)
GEP20135806B (en) Lactams as beta secretase inhibitors